Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Recent Acute Coronary Syndrome (ATLAS ACS 2-TIMI 51)
NCT00809965Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 43
01
Overview
A Phase 3 trial of rivaroxaban in acute coronary syndrome (ACS), sponsored by Johnson & Johnson. Started Nov 2008; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00809965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809965.